MyMD Chief Scientific Officer Adam Kaplin, M.D., Ph.D. will discuss the multiple indications for each of MyMD’s novel drug candidates, MYMD-1 and Supera-CBD.

View More

Back to All News

  • This field is for validation purposes and should be left unchanged.